AnaptysBio Inc
ANAB24.350USD
-0.340-1.38%
交易中 （美东）报价延迟15分钟
739.95M总市值
亏损市盈率 TTM
关于 AnaptysBio Inc 公司
AnaptysBio, Inc. 是一家专注于提供免疫疗法的临床阶段生物技术公司。该公司正在开发免疫细胞调节剂，包括两种用于自身免疫和炎症疾病的检查点激动剂：其 PD-1 激动剂 rosnilimab，正在进行治疗类风湿性关节炎的 2b 期试验和治疗溃疡性结肠炎的 2 期试验；其 BTLA 激动剂 ANB032，正在进行治疗特应性皮炎的 2b 期试验。该公司的临床前免疫细胞调节剂产品组合包括抗 CD122 拮抗剂抗体 ANB033 和 BDCA2 调节剂抗体 ANB101，用于治疗自身免疫和炎症疾病。此外，该公司还开发了两种可供对外授权的细胞因子拮抗剂：imsidolimab，一种抗 IL-36R 拮抗剂，目前处于第 3 阶段，用于治疗全身性脓疱型银屑病或 GPP；etokimab，一种抗 IL-33 拮抗剂，用于治疗呼吸系统疾病，已准备好进行第 2/3 阶段。
公司简介
公司代码ANAB
公司名称AnaptysBio Inc
上市日期Jan 26, 2017
CEOMr. Daniel R. Faga
员工数量136
证券类型Ordinary Share
年结日Jan 26
公司地址10770 Wateridge Circle, Suite 210
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92121
电话18583626295
网址https://www.anaptysbio.com/
公司代码ANAB
上市日期Jan 26, 2017
CEOMr. Daniel R. Faga
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
436.47K
+0.39%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
63.34K
+10.52%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
11.86K
+161.67%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
9.93K
+154.62%
Mr. John A. Orwin
Mr. John A. Orwin
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
9.37K
+180.81%
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
9.36K
+438.05%
Mr. Hollings C. Renton
Mr. Hollings C. Renton
Independent Director
Independent Director
4.96K
--
Mr. Dennis M. Mulroy, CPA
Mr. Dennis M. Mulroy, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Paul F. Lizzul, M.D., Ph.D.
Dr. Paul F. Lizzul, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Dennis Fenton, Ph.D.
Dr. Dennis Fenton, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Daniel R. Faga
Mr. Daniel R. Faga
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
436.47K
+0.39%
Mr. John P. Schmid
Mr. John P. Schmid
Independent Director
Independent Director
63.34K
+10.52%
Dr. Rita Jain, M.D.
Dr. Rita Jain, M.D.
Independent Director
Independent Director
11.86K
+161.67%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
9.93K
+154.62%
Mr. John A. Orwin
Mr. John A. Orwin
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
9.37K
+180.81%
Mr. Eric Joseph Loumeau, J.D.
Mr. Eric Joseph Loumeau, J.D.
Chief Legal Officer
Chief Legal Officer
9.36K
+438.05%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 6月4日 周三
更新时间: 6月4日 周三
持股股东
股东类型
持股股东
持股股东
占比
EcoR1 Capital, LLC
26.82%
First Light Asset Management, LLC
15.77%
Point72 Asset Management, L.P.
8.06%
BlackRock Institutional Trust Company, N.A.
6.24%
Tang Capital Management, LLC
5.26%
Other
37.85%
持股股东
持股股东
占比
EcoR1 Capital, LLC
26.82%
First Light Asset Management, LLC
15.77%
Point72 Asset Management, L.P.
8.06%
BlackRock Institutional Trust Company, N.A.
6.24%
Tang Capital Management, LLC
5.26%
Other
37.85%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
54.45%
Hedge Fund
35.32%
Investment Advisor
28.78%
Research Firm
10.05%
Venture Capital
5.17%
Corporation
2.80%
Individual Investor
2.39%
Bank and Trust
0.20%
Pension Fund
0.11%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
357
40.92M
139.28%
-6.37M
2025Q1
366
43.04M
145.37%
-6.68M
2024Q4
347
37.49M
122.64%
-3.24M
2024Q3
334
34.49M
113.52%
-2.22M
2024Q2
323
30.70M
111.87%
-5.39M
2024Q1
311
29.59M
108.34%
-6.31M
2023Q4
311
30.68M
115.35%
-5.19M
2023Q3
313
31.58M
118.68%
-4.34M
2023Q2
316
31.50M
118.55%
-4.32M
2023Q1
320
32.34M
119.61%
-5.26M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
EcoR1 Capital, LLC
7.88M
26.82%
--
--
Apr 01, 2025
First Light Asset Management, LLC
4.63M
15.77%
-19.47K
-0.42%
Mar 31, 2025
Point72 Asset Management, L.P.
2.37M
8.06%
+677.00K
+40.03%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.83M
6.24%
-174.28K
-8.68%
Mar 31, 2025
Tang Capital Management, LLC
1.55M
5.26%
+214.27K
+16.10%
Mar 31, 2025
The Vanguard Group, Inc.
1.51M
5.16%
-326.42K
-17.73%
Mar 31, 2025
Boxer Capital Management, LLC
1.30M
4.42%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
1.24M
4.24%
-1.05M
-45.76%
Mar 31, 2025
Sofinnova Investments, Inc
1.16M
3.95%
+1.03M
+772.68%
Mar 31, 2025
BofA Global Research (US)
1.14M
3.89%
+1.13M
+6273.39%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco Dorsey Wright Healthcare Momentum ETF
1.18%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
ALPS Medical Breakthroughs ETF
0.44%
Tema Oncology ETF
0.37%
SPDR S&P Biotech ETF
0.15%
iShares Micro-Cap ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Biotechnology ETF
0.06%
查看更多
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.18%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.85%
ALPS Medical Breakthroughs ETF
占比0.44%
Tema Oncology ETF
占比0.37%
SPDR S&P Biotech ETF
占比0.15%
iShares Micro-Cap ETF
占比0.1%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.09%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
Invesco Nasdaq Biotechnology ETF
占比0.07%
iShares Biotechnology ETF
占比0.06%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
